Transgenic mice expressing heterologous complement receptor type 1 (CR1) molecules on erythrocytes and uses therefor
AssigneeUniversity of Massachusetts
InventorRobert W. Finberg
Life of this patent
Estimating the term…
Abstract
The present invention is directed, at least in part, to mice which express exogenous complement receptor type 1 (CR1) on red blood cells. The invention also pertains to genetic constructs encoding heterologous CR1 for expression on red blood cells. Methods of using the transgenic animals of the invention to identify and/or evaluate compositions that can reduce the concentration of an agent, e.g., a biologic agent, in the serum, circulation and/or tissues of a subject are also provided.
Claims24
A transgenic mouse whose genome comprises a polynucleotide encoding human complement receptor 1 (CR1) operably linked to a promoter, wherein the human CR1 molecule is expressed on the surface of erythrocytes of the transgenic mouse, and wherein the human CR1 binds immune complexes.
A method for evaluating the ability of a bispecific compound to reduce the concentration of an agent in the serum and/or circulation of a subject comprising:
- administering the bispecific compound to a transgenic mouse whose genome comprises a polynucleotide encoding human complement receptor 1 (CR1) operably linked to a promoter, wherein the human CR1 is functionally expressed on erythrocytes of the transgenic mouse;
- and
- determining the ability of the bispecific compound to reduce the concentration of the agent in the serum and/or circulation of the transgenic mouse
- to thereby evaluate the ability of the bispecific compound to reduce the concentration of the agent in the serum and/or circulation of the transgenic mouse.
A method for making a transgenic mouse expressing human CR1 on the surface of its erythrocytes comprising:
- a) introducing a polynucleotide encoding a human CR1 polypeptide into an egg or an embryo of a mouse, the polynucleotide operably linked to a promoter which causes human CR1 to be expressed on mouse erythrocytes;
- and
- b) allowing the egg or embryo comprising the CR1 polynucleotide to develop to term to thereby produce a transgenic mouse transgenic mouse whose genome comprises a polynucleotide encoding a human CR1 polypeptide operably linked to a promoter, wherein the human CR1 polypeptide is expressed on the surface of erythrocytes of the transgenic mouse and binds immune complexes.
A method of producing a transgenic mouse, comprising breeding two transgenic mice, genomes of which comprise a polynucleotide encoding a human CR1 polypeptide operably liked to a promoter to thereby produce an offspring transgenic mouse whose genome comprises a polynucleotide encoding a human CR1 polypeptide operably linked to a promoter, wherein the human CR1 polypeptide is expressed on the surface erythrocytes of the transgenic mouse and binds immune complexes.
A method for evaluating the ability of a bispecific compound to bind human CR1 in the serum and/or circulation of a subject comprising:
- administering the bispecific compound to a transgenic mouse whose genome comprises a polynucleotide encoding human complement receptor 1 (CR1) operably linked to a promoter, wherein the human CR1 is expressed on the surface of erythrocytes of the transgenic mouse;
- and
- determining the ability of the bispecific compound to bind human CR1 in the serum and/or circulation of the transgenic mouse;
- to thereby evaluate the ability of the bispecific compound to bind human CR1 in the serum and/or circulation of the transgenic mouse.
Dependencies are inferred from the claim text.